Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Brian H. Nathanson, Ph.D.

President & CEO
OptiStatim LLC

Disclosure(s): cidara: Grant/Research Support; Merck: Advisor/Consultant, Grant/Research Support

Poster(s):

468 - Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
469 - Healthcare Resource Utilization (HRU) among Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received Definitive Treatment with an Echinocandin (EC) Across United States (US) Hospitals
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
663 - Incidence of Acute Kidney Injury (AKI) among Adult Hospitalized Patients (pts) with Carbapenem Resistant Gram-Negative Infections (CR-GNIs) Who Received Early Targeted Treatment (TX) with a Newer β-Lactam (BL)-, Colistin (COL)-, or Aminoglycoside (AG)-Containing Regimen
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET